Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically
modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow
its seed sales substantially.
Scientists are using a new stem-cell technique that may someday revolutionize care for disorders as diverse as diabetes, Alzheimer’s
disease and muscular dystrophy.
Indiana is becoming not only a hotbed of “pharmacogenomics” research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
from cells.
Lilly executives want to make biotech their top focus.
Three months after launching an initiative to boost drug-development firms in Indiana, officials at BioCrossroads have written
a report that attempts to show in detail the vast market opportunity they see.
For the last two months, two academics at Indiana University and Purdue University have been discussing how the institutions
can work together to rev up research in medicine and life sciences and, in the process, boost Indiana’s economy.
Four former top scientists at Eli Lilly and Co. have formed a Carmel-based company to develop diabetes therapies–a venture observers say has the potential to become the kind of blockbuster success BioCrossroads was built to stimulate.
Labs are nearing capacity at Strand Analytical Laboratories, which provides forensic and paternity DNA testing. In the second year of Scott Newman’s business, the former prosecutor predicts 2007 revenue will reach $4 million.
